Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Magenta Therapeutics nets $60.9mm via public offering

Executive Summary

Magenta Therapeutics Inc. (targeted treatments to improve bone marrow transplantation) netted $60.9mm through the public offering of 4.9mm common shares (including the overallotment) at $13.25. Funds will support pipeline advancement, including MGTA145, a first-line mobilization treatment, into Phase II; work to bring stem cell therapy program MGTA456 into Phase III; and additional development projects.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies